These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Alternative splicing of Wilms' tumor suppressor protein modulates DNA binding activity through isoform-specific DNA-induced conformational changes. Laity JH, Chung J, Dyson HJ, Wright PE. Biochemistry; 2000 May 09; 39(18):5341-8. PubMed ID: 10820004 [Abstract] [Full Text] [Related]
5. Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one. Ladomery M, Sommerville J, Woolner S, Slight J, Hastie N. J Cell Sci; 2003 Apr 15; 116(Pt 8):1539-49. PubMed ID: 12640038 [Abstract] [Full Text] [Related]
6. Transactivation of the WT1 antisense promoter is unique to the WT1[+/-] isoform. Moorwood K, Salpekar A, Ivins SM, Hall J, Powlesland RM, Brown KW, Malik K. FEBS Lett; 1999 Jul 30; 456(1):131-6. PubMed ID: 10452544 [Abstract] [Full Text] [Related]
7. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter. Webster NJ, Kong Y, Sharma P, Haas M, Sukumar S, Seely BL. Biochem Mol Med; 1997 Dec 30; 62(2):139-50. PubMed ID: 9441865 [Abstract] [Full Text] [Related]
8. High affinity binding sites for the Wilms' tumour suppressor protein WT1. Hamilton TB, Barilla KC, Romaniuk PJ. Nucleic Acids Res; 1995 Jan 25; 23(2):277-84. PubMed ID: 7862533 [Abstract] [Full Text] [Related]
10. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers. Little MH, Holmes G, Pell L, Caricasole A, Duarte A, Law M, Ward A, Wainwright B. Oncogene; 1996 Oct 03; 13(7):1461-9. PubMed ID: 8875984 [Abstract] [Full Text] [Related]
11. Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein. Laity JH, Dyson HJ, Wright PE. Proc Natl Acad Sci U S A; 2000 Oct 24; 97(22):11932-5. PubMed ID: 11050227 [Abstract] [Full Text] [Related]
12. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B. Hum Mol Genet; 1995 Mar 24; 4(3):351-8. PubMed ID: 7795587 [Abstract] [Full Text] [Related]
14. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Cook DM, Hinkes MT, Bernfield M, Rauscher FJ. Oncogene; 1996 Oct 17; 13(8):1789-99. PubMed ID: 8895526 [Abstract] [Full Text] [Related]
16. Regulation of nov by WT1: a potential role for nov in nephrogenesis. Martinerie C, Chevalier G, Rauscher FJ, Perbal B. Oncogene; 1996 Apr 04; 12(7):1479-92. PubMed ID: 8622864 [Abstract] [Full Text] [Related]